India Seeks To Revive National Vaccine Production Program
This article was originally published in PharmAsia News
Indian authorities are considering a revival of the nation's vaccine-production program to make up for recent declines due to failures to meet international standards. Two Indian companies lost sanction by the World Health Organization because they failed to meet good manufacturing practices standards. But if the government is to revive vaccine production for bacillus calmetteguerin, cholera, diptheria, rabies, tetanus and typhoid, it may have to invest $5 billion in the effort. Among the suggestions is establishment of state-run manufacturing companies to produce vaccines companies complying with World Health Organization standards. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.